| scholarly article | Q13442814 |
| P356 | DOI | 10.2165/11530610-000000000-00000 |
| P8608 | Fatcat ID | release_7j62pnulivdn5nkrwu2mefhdcm |
| P698 | PubMed publication ID | 19888787 |
| P2093 | author name string | Akira Shimada | |
| Hiroshi Hirose | |||
| Satoru Yamada | |||
| Ken Yajima | |||
| Yoichi Oikawa | |||
| Shu Meguro | |||
| Junichiro Irie | |||
| Seiko Irie | |||
| P2860 | cites work | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 |
| Dose finding studies with imidapril--a new ACE inhibitor | Q24538596 | ||
| Angiotensin receptor blockers and myocardial infarction | Q24559659 | ||
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| C-reactive protein (CRP)-lowering agents | Q28200344 | ||
| A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure | Q28328342 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control | Q70979386 | ||
| Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study | Q72369100 | ||
| Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans | Q78149281 | ||
| Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis | Q79969450 | ||
| Do angiotensin II receptor blockers increase the risk of myocardial infarction? | Q81008113 | ||
| Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials | Q31132556 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Plasminogen-activator inhibitor type 1 and coronary artery disease | Q33942520 | ||
| Angiotensin receptor blockers and risk of myocardial infarction: systematic review. | Q34081519 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Q34246891 | ||
| Adiponectin and Metabolic Syndrome | Q34269072 | ||
| Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox | Q34559286 | ||
| Angiotensin receptor blockers do not increase risk of myocardial infarction | Q34559292 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis | Q35552418 | ||
| Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV | Q35766872 | ||
| Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations | Q36035236 | ||
| Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds | Q36306237 | ||
| Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease | Q37123989 | ||
| ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time | Q38486508 | ||
| Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group | Q39522420 | ||
| Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke | Q40551007 | ||
| Prospective study of endogenous tissue plasminogen activator and risk of stroke | Q41036094 | ||
| Endogenous tissue-type plasminogen activator and risk of myocardial infarction | Q41079493 | ||
| Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 | ||
| Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women | Q43756666 | ||
| Blood-pressure reduction and cardiovascular risk in HOPE study | Q43850045 | ||
| Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). | Q43857789 | ||
| Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients | Q43980471 | ||
| Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 | ||
| Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension | Q44471484 | ||
| Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality | Q44727723 | ||
| Plasma adiponectin levels and risk of myocardial infarction in men. | Q44843420 | ||
| Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade | Q45038707 | ||
| Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus | Q46493077 | ||
| Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus | Q46498945 | ||
| Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension | Q46668164 | ||
| Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction | Q46708478 | ||
| Standards of medical care in diabetes--2008. | Q46828447 | ||
| Adiponectin multimeric complexes and the metabolic syndrome trait cluster | Q46870222 | ||
| The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). | Q46951742 | ||
| Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores | Q47857433 | ||
| Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators | Q48118604 | ||
| High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril | Q48326616 | ||
| Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system | Q57583262 | ||
| Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension | Q67800103 | ||
| Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1) | Q70394289 | ||
| P433 | issue | 12 | |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 811-819 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Clinical Drug Investigation | Q15753215 |
| P1476 | title | Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort s | |
| P478 | volume | 29 |
Search more.